Immunic
Immunic

Immunic

Pharmaceuticals
WebsiteInvestor RelationsSEC
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

$105.7M

Market Cap • 11/6/2026

2003

(23 years)

Founded

2014

(12 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

0,8

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

9,4

EPS

—

Market Cap

Market Cap

105,7M

EV

-49M

EV/Revenue

0

EV/EBITDA

0,4

EV/EBIT

0,4

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,1%

Total Yield

-0,1%

Payout

0%

Retained Earnings

-675,3M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

220,8%

Capex/OCF

-0,4%

SBC/OCF

—

% PPE

0,8%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

8,3%

CAGR Net Income 5Y

7,8%

CAGR EPS 5Y

-36%

CAGR OCF 5Y

5,3%

Leverage

N.D./EBITDA

1,3

Debt/Equity

0%

Current Ratio

5

Quick Ratio

5

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium